

Sanochemia Pharmazeutika AG

Notice

The following data represent a snapshot taken at the time of the initial public offering / new listing / inclusion in the MTF and are not updated regularly.

ISIN:	AT0000776307
Symbol:	SAC
Trading segment:	Third Market
Market segment:	mid market
First day of trading:	February 26, 2010
Category:	Ordinary Shares
Company profile:	<i>(Profile provided by the company)</i>

SANOCHEMIA, an Austrian supplier of specialty pharmaceuticals, has specialised in the development and production of innovative substances, drugs and diagnostics. The company's main focus lies on indications with high therapeutic requirements, such as CNS / neurodegeneration, pain and oncology. The marketing and sale of our diagnostic products is yet another fast-growing business area.

As a production-oriented provider of specialty pharmaceuticals, SANOCHEMIA covers the entire value-added chain from the synthesis of premium quality APIs to the GMP-conform manufacture of pharmaceuticals, all of which processes can be performed at the Neufeld site in Austria. Our state-of-the-art logistics centre ships to customers in over 30 countries.

Active pharmaceutical ingredients (APIs) such as galantamine, used in an Alzheimer's drug, enabled the company to establish a foothold in the global pharmaceuticals market. Tolperisone is another development project from SANOCHEMIA's research and development pipeline to go into production, from where it is currently marketed in Germany and Switzerland. Our R&D focus at present lies on innovative projects such as PVP hypericin, for the photodynamic diagnosis and treatment of bladder cancer, and Secrelux®, a pancreatic function diagnostic.

The sale of clinical diagnostics via the subsidiary SANOCHEMIA Diagnostics represents another profitable area of operations. This division's entry into the MRT imaging agents market in 2007 has provided access to the most important segment of the market for imaging diagnostics. The manufacture and marketing of radiological products has now developed to become one of the group's fastest growing areas of operation.